Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Article Title: A Hybrid Implementation-Effectiveness Randomized Trial of CYP2D6 Guided Post-operative Pain Management
doi: 10.1038/s41436-020-01050-4
Figure Lengend Snippet: Implementation Outcomes: Opioid Use Among Study Participants Stratified by Treatment Assignment and CYP2D6 Phenotype High-risk phenotype defined as CYP2D6 IM (intermediate metabolizer), PM (poor metabolizer), UM (ultrarapid metabolizer), or NM-UM (range from NM to UM).
Article Snippet: For participants in the CYP2D6-guided arm, buccal samples were batched each week and processed in the College of American Pathologists/Clinical Laboratory Improvement Amendments-licensed UF Health Pathology Laboratory, and CYP2D6 genotype and metabolizer phenotype results were reported to the electronic health record (EHR).
Techniques: